Discovering targeted
medicines
Redx is a biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease.
RXC004
(Porcupine)
Clinical stage programme designed to unlock the potential of Wnt pathway blockade in oncology.
Proven drug
discovery expertise
Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. The Company has built an attractive portfolio of assets and has a strong proven track record of drug discovery and development. Over the past three years, it has delivered four major preclinical stage transactions, with further clinical and operational key milestones expected in the future. RXC004 is due to start a phase 2 clinical study in patients with advanced malignancies in H2 2021. The Company’s selective ROCK2 inhibitor, RXC007, also entered a phase 1 clinical study in H1 2021.
Latest news
-
11-Oct-2021
Redx Virtual R&D Day with Leading Experts and New Clinical Data for ROCK2 Inhibitor -
20-Sep-2021
Redx Presents Encouraging Phase 1 Data at ESMO for its Porcupine Inhibitor RXC004 in Patients with Advanced Solid Tumours -
13-Sep-2021
RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021
